Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2Phase 2 1

Status

Completed 3Terminated 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5Thoracic 1Sarcoma 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Glioblastoma 5Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Gliosarcoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2330Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1782Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 935Prednisone 925Cetuximab 921Lenalidomide 916Trastuzumab 901

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × depatuxizumab mafodotin × Clear all
NCT02573324 2023-05-11

Intellance1

AbbVie

Phase 3 Completed
691 enrolled 28 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT03419403 2021-04-14

UNITE Study: Understanding New Interventions With GBM ThErapy

AbbVie

Phase 3 Terminated
40 enrolled 16 charts
CNS

Glioblastoma, Neoplasms

NCT02343406 2020-05-22

INTELLANCE-2

AbbVie

Phase 2 Completed
266 enrolled 23 charts
CNS

Brain Neoplasms, Glioblastoma

NCT02365662 2018-03-30

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

AbbVie

Phase 1 Terminated
46 enrolled
BreastCNSGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01800695 2017-11-21

Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme

AbbVie

Phase 1 Completed
202 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡